SAN FRANCISCO — The next generation of anti-restenosis combination products are en route, although a number of observers at this year's Transcatheter Cardiovascular Therapeutics see even the most well-developed version of a bioresorbable stent (BRS) as needing several more years before they will get to market. (Medical Device Daily)